In this article, we will discuss the 8 Oversold Stocks to Buy Right Now.
On June 1, Tom Lee, Fundstrat Managing Partner & Head of Research, and Fundstrat Capital CIO, appeared on CNBC’s ‘Squawk Box’ to discuss the latest market trends. Lee acknowledged the difficult market environment and noted that while 2026 was expected to be a year of turbulence and head fakes, there are still powerful tailwinds for America. These include the AI story and newfound energy independence, which position the US to manage high oil prices. Furthermore, as AI moves downstream, it is benefiting American businesses; Lee explained that S&P earnings for Q1 were $10 higher, amounting to $40 for the year, which, at a 20 multiple, adds 800 points to the S&P. Despite his general bullishness, Lee advised that investors remain vigilant as challenges may persist through December.
Regarding his long-term forecast, Lee maintains that the next two years could see some of the best market activity in history. He attributed this to a confluence of factors, including a US economic growth rate that may accelerate to 4%, a feat he calls astounding for the world’s largest, mature economy. Additionally, the US is a significant exporter of AI products, which are high-value tools for the next 10 to 15 years. He anticipates that capital currently misallocated in private alternatives will move into the public market, and demographic tailwinds, specifically Millennials and Gen Z entering the workforce and inheriting generational wealth, will contribute to significant market gains after 2026.
Lee provided a near-term outlook, suggesting the market could reach 7,700 before experiencing a pullback. He expects June markets to continue building on gains, though not at the pace of May, as money moves downstream into software and AI beneficiaries. Between June and October, however, he warns that the market must digest three major IPOs, navigate potential uncertainty surrounding Kevin Warsh’s new model for inflation, and endure normal seasonality around the midterms. This could lead to a drawdown that might feel like a bear market, similar to the 9% decline experienced between February and April. From October, he believes a very strong rally will commence.
Our Methodology
We used screeners to identify stocks that have declined by at least 30% over the past 3 months but for which analysts see potential to recover (with an average upside potential of at least 30%), and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: All data was sourced on June 4.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
8 Oversold Stocks to Buy Right Now
8. Maze Therapeutics Inc. (NASDAQ:MAZE)
Number of Hedge Fund Holders: 47
Maze Therapeutics Inc. (NASDAQ:MAZE) is one of the oversold stocks to buy right now. On May 12, Maze Therapeutics highlighted in their corporate and financial update positive topline data from the Phase 2 HORIZON trial of MZE829. The trial evaluated the oral inhibitor in patients with APOL1-mediated kidney disease/AMKD. The results provided clinical proof-of-concept, showing meaningful reductions in proteinuria across broad patient populations, including those with focal segmental glomerulosclerosis.
Following these findings, the company is preparing to advance MZE829 into a pivotal trial for moderate AMKD patients without diabetes, which is planned for H1 2027. The company is also progressing its clinical pipeline for MZE782, an oral small molecule targeting PKU and chronic kidney disease. Maze expects to initiate Phase 2 proof-of-concept trials for this candidate by mid-2026 for PKU and in the second half of 2026 for CKD, with topline PKU data anticipated in 2027.
These developments are central to the company’s broader strategy of using genetic insights to address high-unmet needs in metabolic and kidney health. Financially, Maze Therapeutics Inc. maintains a strong position with $528 million in cash and marketable securities, bolstered by an April 2026 registered offering and a $20 million milestone payment. This capital is expected to fund operations into 2029.
Maze Therapeutics Inc. is a developer of small-molecule precision medicines for the treatment of kidney and metabolic illnesses.
7. Celsius Holdings Inc. (NASDAQ:CELH)
Number of Hedge Fund Holders: 52
Celsius Holdings Inc. (NASDAQ:CELH) is one of the oversold stocks to buy right now. On May 7, Celsius Holdings reported record Q1 2026 revenue of $783 million, marking a 138% increase year-over-year. This growth was driven by the recent acquisitions of Alani Nu and Rockstar Energy, as well as the company’s expanded integration within the PepsiCo distribution system. The company achieved a 20.9% dollar share of the US ready-to-drink energy category, with its portfolio contributing nearly half of all growth in the zero-sugar segment.
Financial performance reflected both the scale of the expanded portfolio and ongoing efforts to optimize operations. While gross margin decreased to 48.3% due to the inclusion of the newly acquired brands, management noted improvements in underlying raw material costs and freight structures compared to the previous quarter. The company remains focused on margin expansion throughout the year, utilizing its orbit model and brand integration strategies to streamline costs and enhance profitability.
In addition to strong sales, Celsius Holdings Inc. maintained a disciplined capital allocation strategy, executing $24.1 million in share repurchases during the quarter. With a diverse portfolio, comprising CELSIUS, Alani Nu, and Rockstar Energy, serving different consumer segments, the company expresses confidence in its current momentum.
Celsius Holdings Inc. develops, manufactures, markets, and distributes functional energy drinks globally.
6. Wix.com Ltd. (NASDAQ:WIX)
Number of Hedge Fund Holders: 53
Wix.com Ltd. (NASDAQ:WIX) is one of the oversold stocks to buy right now. On May 13, Wix reported a strong Q1 2026, with bookings of $585 million and revenue of $541 million, reflecting 15% and 14% year-over-year growth. Performance was supported by a 46% surge in new user cohort bookings and the continued success of the Base44 platform, which recently introduced new AI features like Superagents and Figma integration.
The company has shifted Wix Harmony to a proprietary in-house AI model, allowing for greater control over inference costs and improved platform speed. By reducing reliance on third-party technologies, Wix aims to enhance its long-term profitability and create a competitive advantage through its custom-built AI roadmap.
Management reiterated its positive outlook for 2026, citing stable margins and successful capital allocation, including the recent repurchase of nearly 30% of outstanding shares. Wix.com Ltd. continues to see strong momentum, with ARR reaching $150 million in May and high-impact investments successfully expanding its reach into new audiences.
Wix.com Ltd. provides a web development platform for creators, delivering services through a SaaS model. Its products include website templates, website builders, website designs, an app market, web hosting, domain names, website accessibility, a mobile app builder, and an AI website builder.
5. Insulet Corporation (NASDAQ:PODD)
Number of Hedge Fund Holders: 55
Insulet Corporation (NASDAQ:PODD) is one of the oversold stocks to buy right now. On June 3, Insulet launched significant enhancements to its Omnipod 5 Automated Insulin Delivery/AID System in the US, featuring a new 100 mg/dL Target Glucose option. This update allows for greater personalization and improved glycemic control, enabling users to increase their time in range with fewer system interruptions during high glucose events. The rollout is currently underway, with compatible Pods already shipping to retail channels.
Expanding its commitment to user choice and system flexibility, Insulet has also integrated the Omnipod 5 with Abbott’s FreeStyle Libre 3 Plus sensor. This compatibility allows for broader sensor options and includes support for the LibreLinkup app, facilitating easier tracking for caregivers. These updates represent the most substantial algorithm advancement for the platform since its 2022 launch, reinforcing the company’s focus on reducing the daily burden of diabetes management.
Insulet Corporation plans to present further details regarding these advancements at the American Diabetes Association’s 86th Scientific Sessions in New Orleans. By offering more flexible target settings and wider sensor integration, the company aims to remove barriers to AID technology and improve outcomes for people with type 1 and type 2 diabetes. Additional international rollouts for these features are expected to follow later this year.
Insulet Corporation is a medical device company focused on developing, manufacturing, and selling insulin delivery systems for patients with diabetes.
4. Zoetis Inc. (NYSE:ZTS)
Number of Hedge Fund Holders: 57
Zoetis Inc. (NYSE:ZTS) is one of the oversold stocks to buy right now. On May 28, Zoetis received approval from the UK’s Veterinary Medicines Directorate for Lenivia (izenivetmab), a new long-acting monoclonal antibody therapy for alleviating osteoarthritis pain in dogs. Administered as a single injection, the treatment targets nerve growth factor to provide effective pain relief and improved mobility for up to three months.
Osteoarthritis is a prevalent, chronic joint disease affecting nearly 40% of dogs, significantly impacting their quality of life, mobility, and behavior. By offering a long-acting injectable option, Lenivia provides veterinary professionals with a flexible tool to support sustained comfort and manage pain as part of an individualized care plan.
This approval represents a major milestone in the company’s commitment to veterinary innovation and its expanding portfolio of monoclonal antibody therapies. Lenivia is expected to serve as a key advancement in canine pain management, helping address the significant unmet medical needs of dogs suffering from progressive joint conditions.
Zoetis Inc. is a global animal health company that focuses on the discovery, development, manufacture, and commercialization of vaccines, medicines, biodevices, genetic tests, diagnostic products, and precision animal health. Its operations are divided into the United States and International segments.
3. Structure Therapeutics Inc. (NASDAQ:GPCR)
Number of Hedge Fund Holders: 58
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the oversold stocks to buy right now. Structure Therapeutics reported positive Phase 2 results for its oral GLP-1 receptor agonist, aleniglipron, showing up to 16.3% weight loss. With favorable FDA feedback, the company is on track to initiate a Phase 3 registrational trial in Q3 2026.
The company is also advancing its oral amylin receptor agonist pipeline, with lead candidate ACCG-2671 expected to enter multiple ascending dose studies in Q3 and a second candidate, ACCG-3535, beginning clinical trials in Q4. These programs aim to provide accessible oral small-molecule treatments for metabolic diseases.
Financially, Structure Therapeutics Inc. holds $1.5 billion in cash, providing a runway through 2028 to support its clinical programs. Detailed updates on its aleniglipron and amylin portfolios are scheduled for presentation at the American Diabetes Association’s scientific sessions this June.
Structure Therapeutics Inc. is involved in the development and marketing of novel oral small molecule therapies for the treatment of several chronic diseases with unmet medical needs.
2. Roblox Corporation (NYSE:RBLX)
Number of Hedge Fund Holders: 66
Roblox Corporation (NYSE:RBLX) is one of the oversold stocks to buy right now. On May 19, Roblox Corporation authorized its first-ever share repurchase program, allowing the company to buy back up to $3 billion of its common stock, to acquire up to $1 billion over the next twelve months. The initiative is intended to partially offset dilution from employee equity grants while maintaining the company’s financial flexibility to pursue strategic growth.
The program allows for repurchases through various methods, including open market transactions and privately negotiated deals. There is no fixed expiration date for the authorization, and management retains full discretion regarding the timing, price, and volume of shares bought back based on prevailing market conditions and corporate requirements.
CFO Naveen Chopra emphasized that while investing in innovation and growth remains the company’s primary focus, the strength of its balance sheet and free cash flow generation enables this capital allocation strategy. The announcement reflects management’s confidence in Roblox Corporation’s (NYSE:RBLX) long-term business trajectory and its commitment to reducing shareholder dilution.
Roblox Corporation provides online gaming services through its platforms: Roblox Client, Roblox Studio, and Roblox Cloud. The company is based in San Mateo, California and was founded in March 2004 by Erik Cassel and David B. Baszucki.
1. Boston Scientific Corporation (NYSE:BSX)
Number of Hedge Fund Holders: 106
Boston Scientific Corporation (NYSE:BSX) is one of the oversold stocks to buy right now. On May 18, Boston Scientific entered into an accelerated share repurchase/ASR agreement with JPMorgan Chase Bank to buy back $2 billion of its common stock, part of a previously authorized $5 billion program. The company will immediately receive approximately 30.4 million shares, representing 80% of the repurchase value based on the May 15 closing price. The final number of shares will be determined upon completion of the agreement by June 30.
This transaction leaves $3 billion remaining under the company’s total share repurchase authorization. Boston Scientific noted that the ASR is expected to be accretive to its 2026 adjusted earnings per share by $0.02, effectively improving the financial guidance it previously issued in April.
The ASR serves as a key component of Boston Scientific Corporation’s (NYSE:BSX) capital allocation strategy. By using its financial position to reduce share count, the company aims to deliver increased value to shareholders while maintaining resources for its ongoing operational and strategic goals.
Boston Scientific Corporation is a healthcare company, incorporated in 1979, that specializes in medical devices for interventional medical specialties. The company’s segments include MedSurg and Cardiovascular.
READ NEXT: 10 Best Low Risk Stocks to Buy in 2026 and 12 Best High Short Interest Stocks With Highest Upside Potential.
